글로벌 강직증 치료 시장 – 2030년까지의 산업 동향 및 예측

강직증 치료 시장 분석 및 규모

강직증은 일련의 질환으로 인해 발생할 수 있습니다. 강직증은 종종 정신 운동 장애인 긴장증이 뒤따릅니다. 강직증은 긴장증의 12가지 증상 중 하나입니다. 정신 분열증, 간질, 약물 독성 또는 파킨슨병으로 인해 발생할 수 있습니다. 항정신병제와 근육 이완제는 강직증에 도움이 되는 두 가지 치료법입니다.

Data Bridge Market Research는 2023-2030년 예측 기간 동안 강직증 치료 시장의 성장률을 분석합니다. 강직증 시장의 예상 CAGR은 언급된 예측 기간 동안 약 6.20%인 경향이 있습니다. 시장 가치는 2022년에 820억 달러이며, 2030년까지 1,326억 8,000만 달러로 성장할 것입니다. Data Bridge Market Research 팀이 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 시장 세그먼트, 지리적 범위, 시장 참여자 및 시장 시나리오와 같은 시장 통찰력 외에도 심층적인 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크가 포함되어 있습니다.

강직증 치료 시장 범위 및 세분화

시장 정의

강직증은 사지가 어떤 자세를 취하든 그대로 유지되는 자발적 운동성의 현저한 상실 상태입니다. 전형적인 증상으로는 근육 경직, 자발적 운동 상실, 고정된 자세, 통증 민감성 감소가 있습니다. 간질, 약물 남용, 파킨슨병 , 긴장증, 정신 분열증 등 수많은 질병의 징후일 수 있으며, 특정 유형의 정신 분열증 치료 의 부작용일 수도 있습니다 .

강직증 치료 시장 동향

운전자

• 만성 질환의 유병률 증가

만성 질환은 전 세계적으로 증가하고 있습니다. 광범위한 의료 서비스에 대한 접근성의 불평등한 도시 내 불평등은 도시인이 직면한 문제로 이어집니다. 노인, 여성 및 빈곤선 이하에서 사는 사람들은 만성 질환에 걸릴 확률이 더 높습니다. 이러한 사망자의 약 80%는 저소득 및 중소득 국가에서 발생합니다. 만성 질환의 발생률은 전 세계적으로 증가하고 있습니다. 2014년 인도에서 발생한 모든 사망자의 약 60%는 비전염성 질환으로 인한 것이었으며 시간이 지남에 따라 높은 부담이 증가할 것으로 예상됩니다. 일부 흔한 만성 질환은 강직증의 발생률을 다소 증가시키고 있습니다. 이는 치료 시장을 활성화합니다.

기회

• 증가하는 R&D 활동 수    

Numerous projected introduction of many novel developing drugs and widen availability of advantageous reimbursement policies are expected to have much beneficial effects. Other factors that causes the market expansion includes increased government funding for R&D and improved regulatory environment for the healthcare sector. Numerous technological advancements and greater investments in R&D activities have caused the discovery of several novel treatment options. Numerous new trends, such as companies focusing on increase in research and development spending on different neurological disorders are helping to develop novel medicines for treatment of this syndrome. Additionally, numerous clinical trials are conducted on many compounds; and some are in the research process. Several research showed that medications, such as tricyclic antidepressants, zolpidem, benzodiazepines, carbamazepine, and muscle relaxants may prove to be very effective in decreasing the symptoms of catalepsy. In addition to this, pharmacotherapy of Parkinson-induced catalepsy may include dopamine agonists and decarboxylase inhibitors among others. This enhances the market growth.

Restraints/Challenges

• High Cost of Treatment

The increased expenditure that is required for the treatment processes hampers the market growth. Several market players make vast investments in manufacturing new and advanced treatment procedures to improve the recovery process, and thus in return, the cost is increased. This hampers the market growth.

This catalepsy treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the catalepsy treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Catalepsy Treatment Market Scope

The catalepsy treatment market is segmented on the basis of treatment, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment

• Drugs
• Psychotherapy
• Others

Route of Administration

• Oral
• Parenteral
• Others

End-Users

• Hospitals
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacies
• Others

Catalepsy Treatment Regional Analysis/Insights

The catalepsy treatment market is analyzed and market size insights and trends are provided by treatment, route of administration, distribution channel and end-user as referenced above.

The major countries covered in the Catalepsy treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is dominating the market in the forecast period due to the increased incidence of neurological disorders, advanced technology for the diagnosis and treatment in this region.

Asia-Pacific is considered to grow over the coming years because of the continuously increasing population leading to sincreasing prevalence of neurological disorders.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data. 

Competitive Landscape and Global Catalepsy Treatment Share Analysis

The catalepsy treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to catalepsy treatment market

Key players operating in the catalepsy treatment market include:

• GSK Plc. (U.K.)
• Bayer AG (Germany)
• Novartis AG (Switzerland)
• ALEVA NEUROTHERAPEUTICS (Switzerland)
• Sanofi (France)
• Takeda Pharmaceutical Company Limited (Japan)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Abbott (U.S.)
• Pfizer Inc. (U.S.)
• Johnson & Johnson Services, Inc. (India)
• Dr. Reddy’s Laboratories Ltd. (India)
• Mylan N.V. (U.S.)
• Upsher-Smith Laboratories, LLC (U.S.)
• Piramal Enterprises Ltd. (India)
• Vintage Labs (India)
• Hikma Pharmaceuticals PLC (U.K.)
• Endo International plc (Ireland)
• CASI Pharmaceuticals Inc. (U.S.)
• ECI Pharmaceuticals (Florida)
• Bristol-Myers Squibb Company (U.S.)
• Covis Pharma GmbH (Canada)
• Sumitomo Pharma Co., Ltd (Japan)
• Biocon (India), Eisai Co., Ltd (Japan)
• Cipla Inc (India)
• Glenmark Pharmaceuticals Limited (India
• Mankind Pharma(인도)
• Novo Nordisk A/S(덴마크)
• 오츠카 아메리카 제약 주식회사(일본)
• WOCKHARDT(인도)

SKU-52900